알파-갈락토시다아제 관련 복부 팽만 및 가스
B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.라피노스/스타키오스가 함유된 고섬유질 식품으로 인한 가스 증상을 50~70% 줄입니다. 비아노(알파-갈락토시다아제 300 GalU)가 가장 많이 연구된 제형입니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dalpha\u002Dgalactosidase\u0026condition\u003Dbloating\u002Dand\u002Dgas';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
결론
라피노스/스타키오스가 함유된 고섬유질 식품으로 인한 가스 증상을 50~70% 줄입니다. 비아노(알파-갈락토시다아제 300 GalU)가 가장 많이 연구된 제형입니다.
Key Study Findings
Review
Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: None
Randomized Controlled Trial
Double-blind
A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal …
Dose: 1200 G
vs: placebo
Outcome: every 30 min during 7
효과: None
None
대상 집단: patients with ibs after three standardized
Other
n=17
FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument.
Dose: None
vs: no treatment
Outcome: None
효과: None
None
대상 집단: fabry disease but are often nonspecific
Randomized Controlled Trial
n=31
2.0 weeks
Double-blind
Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment.
Dose: 300 GALU or 150 GALU
vs: Placebo (glucose)
Outcome: GI symptom severity on VAS
효과: None
pP0.006
대상 집단: IBS patients (Rome III, H2 producers)
Randomized Controlled Trial
n=125
4 weeks
Double-blind
Does oral α-galactosidase relieve irritable bowel symptoms?
Dose: alpha-galactosidase 600 GalU per meal
vs: placebo
Outcome: overall IBS symptom relief
효과: no significant difference vs placebo
>0.05
대상 집단: IBS patients
Case Reports
A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha …
Dose: 3.7nmol/mL/h
vs: None
Outcome: None
효과: None
None
대상 집단: patients
Key Statistics
4
연구
300
참여자
↑
Positive
B
등급
Referenced Papers
International journal of …
2021
16 인용
Quality of life …
2021
14 인용
Neurogastroenterology and motility
2021
4 인용
The American journal …
2018
49 인용
Scandinavian journal of …
2016
17 인용
Clinical biochemistry
2015
18 인용
BMC gastroenterology
2013
12 인용
Digestive diseases and …
2007
45 인용
Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
Other
Molecular genetics and …
2005
84 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods
- standardbeanodose:
- 300 GalU (2-3 tablets) with first bite of problem food
상한량: No established upper limit; adjust per meal as needed
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| 1200 G | -- | Neutral | -- |
| None | -- | Positive | 17 |
| 300 GALU or 150 GALU | 2.0 weeks | Positive | 31 |
| alpha-galactosidase 600 GalU per meal | 4 weeks | Neutral | 125 |
| 3.7nmol/mL/h | -- | Mixed | -- |
| None | 2 weeks | Positive | -- |
| 300 or 1200 GalU | -- | Positive | 8 |
권장 복용 시간: With the first bite of gas-producing food
Safety & Side Effects
보고된 부작용
- ⚠ Generally very well-tolerated
- ⚠ Rare allergic reactions to mold-derived enzyme (Aspergillus source)
- ⚠ May cause mild GI discomfort in rare cases
알려진 상호작용
- ● Acarbose (alpha-galactosidase may counteract the blood sugar-lowering mechanism of acarbose; contraindicated for concurrent use)
- ● Miglitol (similar mechanism conflict as acarbose)
일일 최대 섭취 허용량: No established upper limit; adjust per meal as needed
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 알파-갈락토시다아제 help with 복부 팽만 및 가스?
Based on 4 studies with 300 participants, there is moderate evidence from clinical studies that 알파-갈락토시다아제 may support 복부 팽만 및 가스 management. Our evidence grade is B (Good Evidence).
How much 알파-갈락토시다아제 should I take for 복부 팽만 및 가스?
Studies have used various dosages. A commonly studied range is 150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 알파-갈락토시다아제?
Reported side effects may include Generally very well-tolerated, Rare allergic reactions to mold-derived enzyme (Aspergillus source), May cause mild GI discomfort in rare cases. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 알파-갈락토시다아제 and 복부 팽만 및 가스?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 복부 팽만 및 가스
알파-갈락토시다아제 다른 건강 상태에 대한 근거
References
- [1] Fabio Caputo et al.. Int J Environ Res Public Health. 2021. Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review. doi:10.3390/ijerph18063320 PubMed
- [2] Alan L Shields et al.. Qual Life Res. 2021. FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument. doi:10.1007/s11136-021-02847-9 PubMed
- [3] Lena Böhn et al.. Neurogastroenterol Motil. 2021. A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in irritable bowel syndrome … doi:10.1111/nmo.14094 PubMed
- [4] C J Tuck et al.. Am J Gastroenterol. 2018. Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. doi:10.1038/ajg.2017.245 PubMed
- [5] Markku Hillilä et al.. Scand J Gastroenterol. 2016. Does oral α-galactosidase relieve irritable bowel symptoms? doi:10.3109/00365521.2015.1063156 PubMed
- [6] Antonino Tuttolomondo et al.. Clin Biochem. 2015. A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene. doi:10.1016/j.clinbiochem.2014.09.018 PubMed
- [7] Giovanni Di Nardo et al.. BMC Gastroenterol. 2013. Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial. doi:10.1186/1471-230X-13-142 PubMed
- [8] Michele Di Stefano et al.. Dig Dis Sci. 2007. The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. doi:10.1007/s10620-006-9296-9 PubMed
- [9] Maryam Banikazemi et al.. Mol Genet Metab. 2005. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. doi:10.1016/j.ymgme.2005.04.009 PubMed
- [10] T G Ganiats et al.. J Fam Pract. 1994. Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.